Human CD38 Recombinant Protein (RPES4814)
- SKU:
- RPES4814
- Product type:
- Recombinant Protein
- Host species:
- Human Cells
- Reactivity:
- Human
Frequently bought together:
Description
system_update_alt데이터시트
Human CD38 Recombinant Protein
CD38; also called ADP-ribosyl cyclase; is a Type II integral membrane protein with 301 amino acids in length that belongs to the ADP-ribosyl cyclase family.It synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate; the former a second messenger for glucose-induced insulin secretion. And also moonlights as a receptor in cells of the immune system. CD38 is expressed in B and T lymphocytes; osteoclasts; and in cardiac; pancreatic; liver and kidney cells. Through its production of cyclic ADP-ribose; CD38 modulates calcium-mediated signal transduction in many types of cells; including neutrophils and pancreatic beta cells.
Product Name: | Human CD38 Recombinant Protein (RPES4814) |
Product Code: | RPES4814 |
Size: | 10µg |
Species: | Human |
Expressed Host: | Human Cells |
Synonyms: | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase 1, Cyclic ADP-ribose hydrolase 1, CD38 antigen, CD38 molecule,CD38 |
Accession: | P28907 |
Sequence: | Val43-Ile300 |
Fusion tag: | C-Fc |
Endotoxin: | <1.0 EU per µg as determined by the LAL method. |
Protein Construction: | Recombinant Human CD38 is produced by our Mammalian expression system and the target gene encoding Val43-Ile300 is expressed with a Fc tag at the C-terminus. |
Purity: | > 95% as determined by reducing SDS-PAGE. |
Mol Mass: | 57 kDa |
AP Mol Mass: | 70-90 kDa |
Formulation: | Lyophilized from a 0.2 µm filtered solution of PBS; pH7.4. |
Shipping: | This product is provided as lyophilized powder which is shipped with ice packs. |
Stability and Storage: | Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |